Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials

Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we investigated the effects of tofacitinib on patient-reported outcomes (PRO) in patients with active RA. Two, 6-month, double-blind, placebo-controlled Phase 2b studies were performed. The combination...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical and experimental rheumatology 2016-05, Vol.34 (3), p.430-442
Hauptverfasser:	Wallenstein, Gene V, Kanik, Keith S, Wilkinson, Bethanie, Cohen, Stanley, Cutolo, Maurizio, Fleischmann, Roy, Genovese, Mark C, Gomez Reino, Juan, Gruben, David, Kremer, Joel, Krishnaswami, Sriram, Lee, Eun Bong, Pascual-Ramos, Virginia, Strand, Vibeke, Zwillich, Samuel H
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antirheumatic Agents - administration & dosage Antirheumatic Agents - adverse effects Arthralgia - drug therapy Arthralgia - physiopathology Arthralgia - psychology Arthritis, Rheumatoid - diagnosis Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - immunology Arthritis, Rheumatoid - physiopathology Disease Resistance Drug Administration Schedule Drug Monitoring Female Humans Janus Kinases - antagonists & inhibitors Male Middle Aged Pain Measurement - methods Piperidines - administration & dosage Piperidines - adverse effects Pyrimidines - administration & dosage Pyrimidines - adverse effects Pyrroles - administration & dosage Pyrroles - adverse effects Quality of Life Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!